Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02663193 · ClinicalTrials.gov registry record
Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability
A clinical trial of Prostate Cancer, sponsored by Janssen Scientific Affairs.
- Completed
- Registry status
- 108
- Enrollment target
- 20
- Study locations
NCT02663193: Completed study of Prostate Cancer, sponsored by Janssen Scientific Affairs.
NCT02663193 is a study of Prostate Cancer that has completed, run by Janssen Scientific Affairs. The registered enrollment target is 108 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02663193, a study of Prostate Cancer, has completed, sponsored by Janssen Scientific Affairs.
- COMPLETED
- Registry status
- 108 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to characterize the tolerability profiles of enzalutamide and abiraterone acetate (with prednisone) -with specific focus on central nervous system (CNS) tolerability-and quality of life (QoL) after approximately 2 months of participants starting treatment with one of these agents for metastatic castration-resistant prostate cancer (mCRPC).
Primary Outcome
The Cogstate computerized cognitive test battery will be used as the assessment tool in this study. Overall, Cogstate measures a range of cognitive functions (example, psychomotor and memory function) using a number of different tests (example, choice reaction time, one-back memory). This battery of tests was chosen because it has been shown to be sensitive to very small cognitive changes and has been tested in cancer participants after chemotherapy.
Conditions Studied
Interventions
- OTHER No Intervention
Study Locations (20)
New Jersey
- - Englewood
- - Lawrenceville
- - Morristown
Indiana
- - Indianapolis
- - Jeffersonville
New York
- - Poughkeepsie
- - Syracuse
Pennsylvania
- - Bala-Cynwyd
- - Lancaster
South Carolina
- - Charleston
- - Myrtle Beach
Alabama
- - Homewood
California
- - La Mesa
Colorado
- - Wheat Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2015-12 |
| Est. Completion | 2017-01 |
What the finished NCT02663193 record still lists
NCT02663193 is an observational study that tracks outcomes without assigning an intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT02663193 names 20 study sites across 14 states, led by New Jersey, Indiana, New York.
Frequently Asked Questions
What is clinical trial NCT02663193 about?
NCT02663193 is a clinical study titled "Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability". The purpose of this study is to characterize the tolerability profiles of enzalutamide and abiraterone acetate (with prednisone) -with specific focus on central nervous system (CNS) tolerability-and quality of life (QoL) after approximately 2 months of participants starting treatment with one of the...
What is the current status of trial NCT02663193?
This trial is currently completed. The enrollment target is 108 participants. The study started on 2015-12. Estimated completion is 2017-01.
What conditions does trial NCT02663193 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT02663193?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT02663193?
This trial is sponsored by Janssen Scientific Affairs, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02663193 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02663193's enrollment target sits among peer trials
108 323rd of 735 higher than 413 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT03848663 · 108 participants · NA
Visual Remapping to Aid Reading With Field Loss
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia